CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)

  • Etude concernée: IFCT-1401
  • Auteurs / Authors: G. Goss, G.E. Darling, V. Westeel, K. Nakagawa, B. Massuti Sureda, F. Perrone, S-A. McLachlan, J.H. Kang, Y-L. Wu, A-M.C. Dingemans, R. Dziadziuszko, M. Okada, L. Greillier, C. Audigier-Valette, S. Sugawara, E. Nadal, A. Catino, M.R. Stockler, K. Ding, C. O’Callaghan
  • Journal / Conference: ESMO
  • Année / Year: 2024
  • PMID: Oral abstract
  • Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(24)03869-9/fulltext